论文部分内容阅读
目的探讨灯盏花素注射液联合阿司匹林治疗急性缺血性脑梗死的临床效果。方法收集延安大学咸阳医院2012年1月—2015年3月收治的急性脑梗死患者300例,随机分为观察组和对照组各150例。对照组采用急性缺血性脑梗死对症治疗,观察组在对症治疗的基础上,加用灯盏花素注射液和口服阿司匹林进行治疗。两组治疗前后采用美国国立卫生研究所脑卒中评分表(NIHSS)进行评分;采用酶联免疫吸附试验检测血清白介素-6(IL-6)和肿瘤坏死因子(TNF-α)水平。治疗4周后,对两组进行临床疗效判定。结果观察组与对照组治疗前NIHSS评分比较,差异无统计学意义,而治疗后观察组NIHSS评分低于对照组,差异具有统计学意义(P<0.05);治疗后,两组IL-6和TNF-α水平均低于治疗前,差异具有统计学意义(P<0.05);且观察组中IL-6和TNF-α水平均低于对照组,差异具有统计学意义(P<0.05);观察组临床总有效率达92.67%,高于对照组的78.00%,差异具有统计学意义(P<0.05)。结论在急性缺血性脑梗死患者中,应用灯盏花素注射液联合阿司匹林肠溶片能够改善临床症状,降低炎症因子水平,显著提高临床疗效,值得推广。
Objective To investigate the clinical effect of breviscapine injection combined with aspirin in the treatment of acute ischemic cerebral infarction. Methods 300 patients with acute cerebral infarction who were treated in Xianyang Hospital of Yan’an University from January 2012 to March 2015 were randomly divided into observation group (150 cases) and control group (150 cases). The control group was given symptomatic treatment of acute ischemic cerebral infarction. The observation group was treated with breviscapine injection and oral aspirin on the basis of symptomatic treatment. The scores of NIHSS before and after treatment in both groups were scored. The levels of serum IL-6 and TNF-α were detected by enzyme linked immunosorbent assay (ELISA). After 4 weeks of treatment, the clinical efficacy was evaluated in both groups. Results There was no significant difference in NIHSS score between the observation group and the control group before treatment, but the NIHSS score of the observation group was lower than that of the control group after treatment (P <0.05). After treatment, the levels of IL-6 and (P <0.05). The levels of IL-6 and TNF-α in the observation group were lower than those in the control group (P <0.05), and the difference was statistically significant (P <0.05). The total effective rate in the observation group was 92.67%, which was higher than that in the control group (78.00%), the difference was statistically significant (P <0.05). Conclusion In patients with acute ischemic stroke, the application of breviscapine injection combined with aspirin enteric-coated tablets can improve the clinical symptoms, reduce the level of inflammatory cytokines and significantly improve the clinical efficacy, which is worth promoting.